Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Non-Hodgkin lymphoma diagnosed through subconjunctival mass: 3 years follow-up

Poster Details

First Author: M.Gessa SPAIN

Co Author(s):    M. Parrilla Vallejo   I. Relimpio Lopez                 

Abstract Details

Purpose:

To describe the case of a patient with subconjunctival mass diagnosed as non-Hodgkin lymphoma, treatment and evolution in three years

Setting:

Virgen Macarena University Hospital Seville, Spain

Methods:

Clinical case. Images are attached

Results:

Male, 70 years with conjunctival lesion. Review: BCVA: RE: 0.8; LE:1.0. BMC: solid subconjunctival lesion pink salmon lesion, between limbo and wattles. In suspected lymphoma conjunctival resection is decided with safety margins and cryotherapy. Histopathological examination revealed diffuse Non Hodgkin giant cells positive to CD10, CD20, BCL2 and CD 45. . Cancer extension study: lymphadenopathy nodes in cervical, mediastinal and abdominal diagnosed.PET: supradiaphragmatic and infradiaphragmatic involvement with hypermetabolic nodule in right arm suggestive malignancy. Chemotherapy regimen R-CHOP, six cycles, one every 21 days. After 3 years of treatment, have completely disappeared all injuries and is considered cured of this disease.

Conclusions:

A lonely orbital tumor does not rule out systemic disease associated. You need a systemic study because, as we have seen, 75% of orbital tumors are secondary. Hence the importance of early diagnosis by the ophthalmologist, since it raises the possibility of establishing a chemotherapy treatment, which involves the elimination of any possible undetected focus extraorbital and decreases the rate of distant recurrences.

Financial Disclosure:

NONE

Back to Poster listing